Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Non-Current Liabilities (2018 - 2019)

Iovance Biotherapeutics has reported Other Non-Current Liabilities over the past 4 years, most recently at $53000.0 for Q3 2019.

  • Quarterly results put Other Non-Current Liabilities at $53000.0 for Q3 2019, changed N/A from a year ago — trailing twelve months through Sep 2019 was $53000.0 (changed N/A YoY), and the annual figure for FY2018 was $230000.0, changed.
  • Other Non-Current Liabilities for Q3 2019 was $53000.0 at Iovance Biotherapeutics, roughly flat from $53000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for IOVA hit a ceiling of $230000.0 in Q4 2018 and a floor of $53000.0 in Q1 2019.